Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History AVDL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics AVDL

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Avadel Pharmaceuticals PLC

AVDL
Current price
9.77 USD +0.25 USD (+2.63%)
Last closed 9.04 USD
ISIN IE00BDGMC594
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 865 321 472 USD
Yield for 12 month -40.57 %
1Y
3Y
5Y
10Y
15Y
AVDL
21.11.2021 - 28.11.2021

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. Address: 10 Earlsfort Terrace, Dublin, Ireland, D02 T380

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

16.57 USD

P/E Ratio

Dividend Yield

Financials AVDL

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures AVDL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+169 117 000 USD

Last Year

+27 963 000 USD

Current Quarter

+52 511 000 USD

Last Quarter

+50 410 000 USD

Current Year

+153 840 000 USD

Last Year

+27 117 000 USD

Current Quarter

+46 934 000 USD

Last Quarter

+45 598 000 USD
EBITDA -16 400 000 USD
Operating Margin TTM -5.72 %
Price to Earnings
Return On Assets TTM -7.21 %
PEG Ratio 0.070
Return On Equity TTM -34.65 %
Wall Street Target Price 16.57 USD
Revenue TTM 194 450 000 USD
Book Value 0.77 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 93.20 %
Dividend Yield
Gross Profit TTM 175 118 000 USD
Earnings per share -0.26 USD
Diluted Eps TTM -0.26 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -13.58 %

Stock Valuation AVDL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 15.15
Enterprise Value Revenue 4.12
Price Sales TTM 4.45
Enterprise Value EBITDA -6.43
Price Book MRQ 11.68

Technical Indicators AVDL

For 52 Weeks

6.38 USD 17.30 USD
50 Day MA 9.18 USD
Shares Short Prior Month 11 334 927
200 Day MA 9.98 USD
Short Ratio 8.85
Shares Short 10 615 388
Short Percent 12.80 %